Werewolf Therapeutics Stock Doubles on Ambros Merger; Legacy Holders Get 6.8%
Werewolf Therapeutics shares doubled after announcing a merger with Ambros Therapeutics. Existing shareholders will hold only 6.8% of the combined entity, with a $150 million PIPE funding the lead drug program.
IPO
